SCHEMBL23590117

SCHEMBL23590117

COc1ccc(-c2ccc(-c3cc(C(=O)O)c4cc(C(F)(F)F)ccc4n3)nc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 6/20 0.53
▸ KDM4E B2RXH2 4/20 0.53
▸ PLA2G2A P14555 3/20 0.51
▸ RUVBL1 Q9Y265 1/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ HSD17B10 Q99714 2/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ ALDH1A1 P00352 2/20 0.47
▸ HPGD P15428 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ NFKB1 P19838 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ NFKB2 Q00653 1/20 0.47
▸ RELA Q04206 1/20 0.47
▸ ATM Q13315 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ PTPN11 Q06124 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23590053 0.91 DHODH (0.53) DHODHKDM4EPLA2G2ARUVBL1SMN1; SMN2
SCHEMBL23590219 0.91 KDM4E (0.55) DHODHKDM4ESMN1; SMN2HSD17B10MEN1
SCHEMBL23590039 0.90 DHODH (0.48) DHODHKDM4EPLA2G2ARUVBL1SMN1; SMN2
SCHEMBL23590055 0.90 DHODH (0.50) DHODHKDM4EPLA2G2ARUVBL1SMN1; SMN2
SCHEMBL23590146 0.90 DHODH (0.62) DHODHKDM4ERUVBL1SMN1; SMN2HSD17B10
SCHEMBL23590061 0.89 DHODH (0.59) DHODHKDM4EPLA2G2ASMN1; SMN2HSD17B10
SCHEMBL23590051 0.89 DHODH (0.54) DHODHKDM4EPLA2G2ASMN1; SMN2HSD17B10
SCHEMBL23590078 0.89 KDM4E (0.65) DHODHKDM4EPLA2G2ARUVBL1SMN1; SMN2
SCHEMBL23590063 0.88 DHODH (0.48) DHODHKDM4EPLA2G2ASMN1; SMN2HSD17B10
SCHEMBL23590040 0.88 DHODH (0.46) DHODHKDM4ESMN1; SMN2HSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed
US-20230109418-A1 COMPOSITIONS FOR USE FOR THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION (US) 2023-04-06 — — US disclosed
WO-2023278778-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD47-SIRPΑ THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-01-05 — — WO disclosed
WO-2021133831-A1 COMPOSITIONS FOR USE FOR THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION (US) 2021-07-01 — — WO disclosed
WO-2021134045-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2021-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD DHODH 1/4885KDM4E 1396/4885PLA2G2A 1679/4885
US-20230109418-A1 COMPOSITIONS FOR USE FOR THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE DHODH, DDO, DLD DHODH 1/4885KDM4E 992/4885PLA2G2A 3187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback